Inactive Instrument

BioNTech SE Stock Xetra

Equities

US09075V1026

Biotechnology & Medical Research

Financials

Sales 2024 * 2.75B 2.94B 4.04B Sales 2025 * 2.75B 2.94B 4.04B Capitalization 20.77B 22.23B 30.55B
Net income 2024 * -419M -448M -616M Net income 2025 * -548M -586M -806M EV / Sales 2024 * 2.95 x
Net cash position 2024 * 12.67B 13.56B 18.64B Net cash position 2025 * 12.02B 12.86B 17.68B EV / Sales 2025 * 3.18 x
P/E ratio 2024 *
-47.6 x
P/E ratio 2025 *
-37.7 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
Indonesia ramps up fight against tuberculosis amid concerns on economic impact RE
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say RE
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading MT
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab CI
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower MT
BioNTech, CEPI Expand Partnership for mRNA Vaccine Ecosystem in Africa MT
BioNTech gets $145 mln funding for African vaccine plants RE
BioNTech and CEPI Expand Partnership to Strengthen Africa?s mRNA Vaccine Ecosystem CI
BioNTech wins up to $145 mln in CEPI support for African mRNA vaccine plants RE
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading MT
BioNTech Collaborating with MediLink to Develop More Potential Antibody-Drug Conjugate, Immunotherapy Treatments MT
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower MT
More news
Managers TitleAgeSince
Chief Executive Officer 58 08-06-01
Founder 57 08-06-01
Director of Finance/CFO 60 21-06-30
Members of the board TitleAgeSince
Director/Board Member 70 21-12-31
Director/Board Member 67 08-06-01
Chairman 53 08-06-01
More insiders
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company